Danaher Corporation has entered into an agreement to acquire privately-held Aldevron for approximately $9.6 billion.
 
Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is headquartered in Fargo, ND and employs approximately 600 people. Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment.
 
“We are thrilled to have Aldevron join Danaher’s Life Sciences segment,” said Rainer M. Blair, president and CEO, Danaher. “For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster.”
 
Michael Chambers, founder and executive chairman, Aldevron, said, “Joining Danaher will help us expand our global reach and harness the power of the Danaher Business System to continue supporting our customers with best-in-class products and services. I’m incredibly excited for Aldevron to take this pivotal next step with Danaher and look forward to the tremendous impact we can make together in the expanding area of genomic medicine.”